For many years, cancer research focused almost entirely on the tumour itself. Scientists studied abnormal cells, genetics, tumour growth, and the effects of chemotherapy or radiation. But a rapidly expanding area of research is now changing the way we think about cancer completely — the microbiome.
The microbiome refers to the enormous ecosystem of bacteria, fungi, and microorganisms living inside the digestive tract. Once thought to play a relatively minor role in health, the microbiome is now recognised as one of the most influential biological systems in the body. It interacts continuously with the immune system, inflammatory pathways, metabolism, hormone signalling, and even neurological function.
In recent years, researchers have begun asking a fascinating question:
Could the gut microbiome influence how cancer develops, how patients respond to treatment, and even how long they survive?
In human medicine, the answer increasingly appears to be yes. Now veterinary researchers are beginning to uncover similar patterns in dogs.
At Biome4Pets, we are currently involved in ongoing microbiome research collaborations with IBERS and Aberystwyth University, exploring the role of the microbiome in canine health, disease resilience, inflammation, and metabolism. One of the most exciting emerging areas of this research is the relationship between gut bacteria and canine cancer.
The Gut Is Closely Linked to the Immune System
To understand why the microbiome may matter in cancer, it helps to understand just how connected the gut is to the immune system.
Around 70% of immune tissue is associated with the gastrointestinal tract. The gut is not simply responsible for digestion — it acts as one of the body’s largest immune control centres. The bacteria living there constantly communicate with immune cells, helping regulate inflammatory responses and teaching the immune system how to react appropriately to threats.
In a healthy dog, the microbiome helps maintain balance. Beneficial bacteria produce compounds called short-chain fatty acids, help strengthen the gut lining, regulate inflammatory signalling, and support immune stability. But when this ecosystem becomes disrupted — a condition known as dysbiosis — the consequences can spread far beyond the digestive system.
Scientists now believe dysbiosis may contribute to chronic inflammation, oxidative stress, altered immune responses, and metabolic dysfunction, all of which are factors associated with cancer biology.
This does not mean bacteria directly “cause” cancer in a simple sense. Cancer is an extraordinarily complex disease involving genetics, age, environmental exposures, immune regulation, hormones, and many other influences. However, the microbiome may help create either a healthier internal environment that resists disease or one that becomes more permissive to inflammation and tumour progression.
Dogs With Different Microbiomes May Respond Differently to Cancer
One of the most exciting veterinary oncology studies in recent years came from Oregon State University, where researchers investigated whether gut bacteria could influence survival outcomes in dogs receiving cancer treatment.
The findings were remarkable.
Researchers discovered that dogs receiving immunotherapy appeared to survive either longer or shorter depending on the composition of their gut microbiome. Certain bacterial populations were associated with improved outcomes, while others were linked to poorer survival.
This is a major development because it suggests the microbiome may actively influence how well cancer therapies work.
For years, veterinarians have observed that two dogs with seemingly similar cancers can respond very differently to treatment. Some tolerate chemotherapy exceptionally well and maintain stable health for long periods, while others experience significant complications or poor responses. Traditionally, these differences were largely attributed to tumour biology or individual variation.
Now researchers suspect the microbiome may be one of the hidden variables helping explain these differences.
The idea that gut bacteria could influence survival may sound extraordinary, but similar findings are already being reported repeatedly in human oncology. In human cancer medicine, the microbiome has been shown to influence responses to immunotherapy, chemotherapy toxicity, and overall treatment outcomes.
Veterinary medicine now appears to be following the same scientific direction.
Can the Microbiome Predict Chemotherapy Side Effects?
Another major study currently underway at the Royal Veterinary College is exploring whether a dog’s microbiome before treatment could help predict which patients are more likely to experience chemotherapy-related complications.
The RVC “Gut Instinct” project is investigating whether faecal microbiome analysis may identify dogs at greater risk of gastrointestinal side effects such as diarrhoea, vomiting, inflammation, or poor treatment tolerance during chemotherapy.
This area of research is incredibly important because chemotherapy does not only affect cancer cells. It also places enormous stress on the digestive system and the intestinal lining.
Many chemotherapy drugs unintentionally damage rapidly dividing cells within the gut. When this happens, the microbiome itself can become disrupted, beneficial bacteria may decline, inflammatory bacteria may increase, and gut barrier integrity can weaken. This can contribute to nausea, digestive instability, inflammation, reduced appetite, and increased susceptibility to secondary complications.
Researchers are now asking whether dogs that already have unstable microbiomes before treatment may be less resilient during chemotherapy.
If this proves true, microbiome analysis could eventually become part of supportive oncology care, helping veterinarians identify vulnerable patients earlier and provide more targeted nutritional and gastrointestinal support.
Chemotherapy May Disrupt the Microbiome Itself
Interestingly, recent studies also suggest the relationship works both ways — cancer treatment may alter the microbiome just as the microbiome may influence treatment outcomes.
A veterinary oncology study investigating dogs with lymphoma found that chemotherapy caused measurable changes to the gut microbiome within just one week of treatment. Researchers observed increased dysbiosis, reductions in beneficial bacterial populations, and alterations in microbial metabolites associated with gut health.
This may help explain why gastrointestinal side effects are so common during cancer treatment.
When the microbiome becomes disrupted, the consequences may extend beyond digestion alone. The microbiome influences inflammatory signalling, immune regulation, nutrient metabolism, and gut barrier function. Once dysbiosis develops, it may potentially worsen inflammation and reduce overall resilience during treatment.
Researchers are increasingly interested in whether preserving microbiome stability during cancer therapy could improve quality of life and treatment tolerance in canine patients.
Could the Microbiome Influence Cancer Risk?
One of the biggest unanswered questions is whether long-term microbiome imbalance could influence cancer risk itself.
Human studies increasingly link chronic dysbiosis with various cancers, including colon, breast, pancreatic, liver, and lung cancer. Scientists believe this relationship may involve several overlapping mechanisms, including chronic low-grade inflammation, oxidative stress, altered bile acid metabolism, bacterial toxin production, and impaired immune surveillance.
Dogs possess many of these same biological systems, making it entirely plausible that similar mechanisms may exist in canine disease.
Although veterinary research is still in its early stages, scientists suspect that persistent microbiome imbalance could contribute to an inflammatory internal environment that may make disease progression more likely over time.
Again, this does not mean microbiome imbalance alone causes cancer. Rather, it may represent one piece of a much larger biological puzzle.
A New Direction in Veterinary Medicine
What makes this field so exciting is that it is shifting the way we think about disease entirely.
The microbiome is no longer viewed simply as “gut bacteria.” It is increasingly recognised as a highly active biological organ influencing immune function, inflammation, metabolism, neurological signalling, and systemic health throughout the body.
In the future, microbiome analysis may potentially help veterinarians:
-
better predict treatment responses,
-
identify dogs at higher risk of chemotherapy complications,
-
monitor inflammatory health,
-
improve supportive care during treatment,
-
and potentially even guide personalised therapeutic strategies.
Some human cancer centres are already exploring microbiome-targeted therapies, including precision probiotics, microbial metabolite therapies, dietary interventions, and faecal microbiota transplantation.
Veterinary medicine may eventually move in similar directions as the science develops further.
What This Means for Dog Owners
It is important to remain realistic and scientifically balanced. Microbiome testing is not currently a cancer diagnostic tool, nor can it replace imaging, biopsies, oncology consultations, or conventional cancer treatment.
However, the emerging research strongly suggests that the microbiome may provide valuable insight into a dog’s inflammatory health, immune resilience, gastrointestinal stability, and treatment tolerance.
What is becoming increasingly clear is that the gut microbiome is deeply connected to overall health in ways we are only beginning to understand.
Just a few years ago, the idea that gut bacteria could influence cancer survival would have sounded implausible. Today, it is one of the most rapidly expanding areas in both human and veterinary medicine.
And in dogs, we are only at the beginning of discovering how important this hidden ecosystem may truly be.
